Activational and effort-related aspects of motivation: Neural mechanisms and implications for psychopathology

Brain

Volumn 139, Issue 5, 2016, Pages 1325-1347

  Salamone, John D ^a   Yohn, Samantha E ^a   López Cruz, Laura ^b   San Miguel, Noemí ^b   Correa, Mercè ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITAT JAUME I   (Spain)

Author keywords

anergia; depression; dopamine; fatigue; reward

Indexed keywords

ADENOSINE A2 RECEPTOR; ANTIDEPRESSANT AGENT; CYTOKINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE TRANSPORTER; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN;

CATECHOLAMINE UPTAKE; DECISION MAKING; DEPRESSION; DOPAMINE BRAIN LEVEL; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; FATIGUE; FOREBRAIN; HUMAN; LASSITUDE; MENTAL DISEASE; MOTIVATION; NONHUMAN; NUCLEUS ACCUMBENS; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; PSYCHOMOTOR RETARDATION; REINFORCEMENT; REVIEW; REWARD; SCHIZOPHRENIA; ANIMAL; EXERCISE; MAJOR DEPRESSION; NERVE TRACT; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; DECISION MAKING; DEPRESSIVE DISORDER, MAJOR; DOPAMINE; HUMANS; MOTIVATION; NEURAL PATHWAYS; PARKINSON DISEASE; PHYSICAL EXERTION; SCHIZOPHRENIA;

EID: 84966573852     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aww050     Document Type: Review

References (251)

1. Aberman JE, Ward SJ, Salamone JD. Effects of dopamine antagonists and accumbens dopamine depletions on time-constrained progressive ratio performance. Pharmacol Biochem Behav 1998; 61: 341-8.
2. Aarts E, Helmich RC, Janssen MJ, Oyen WJ, Bloem BR, Cools R. Aberrant reward processing in Parkinson's disease is associated with dopamine cell loss. Neuroimage 2012; 59: 3339-46.
3. Aberman JE, Salamone JD. Nucleus accumbens dopamine depletions make animals more sensitive to high ratio requirements but do not impair primary food reinforcement. Neuroscience 1999; 92: 545-55.
4. Achterberg EJ, van Kerkhof LW, Servadio M, van Swieten MM, Houwing DJ, Aalderink M, et al. Contrasting roles of dopamine and noradrenaline in the motivational properties of social play behavior in rats. Neuropsychopharmacology 2016; 41: 858-68.
5. Amsterdam JD, Settle RG, Doty RL, Abelman E, Winokur A. Taste and smell perception in depression. Biol Psychiatry 1987; 22: 1481-5.
6. Anstrom KK, Woodward DJ. Restraint increases dopaminergic burst firing in awake rats. Neuropsychopharmacology 2005; 30: 1832-40.
7. Anstrom KK, Miczek KA, Budygin EA. Increased phasic dopamine signaling in the mesolimbic pathway during social defeat in rats. Neuroscience 2009; 161: 3-12.
8. Aparicio CF. Haloperidol, dynamics of choice, and the parameters of the matching law. Behav Process 2007; 75: 206-12.
9. Artaloytia JF, Arango C, Lahti A, Sanz J, Pascual A, Cubero P, et al. Negative signs and symptoms secondary to antipsychotics: a doubleblind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. Am J Psychiatry 2006; 163: 488-93.
10. Baldo BA, Sadeghian K, Basso AM, Kelley AE. Effects of selective dopamine D1 or D2 receptor blockade within nucleus accumbens subregions on ingestive behavior and associated motor activity. Behav Brain Res 2002; 137: 165-77.
11. Barch DM, Dowd EC. Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions. [Review]. Schizophr Bull 2010; 36: 919-34.
12. Barch DM, Treadway MT, Schoen N. Effort, anhedonia, and function in schizophrenia: reduced effort allocation predicts amotivation and functional impairment. J Abnorm Psychol 2014; 123: 387-97.
13. Barch DM, Pagliaccio D, Luking K. Mechanisms underlying motivational deficits in psychopathology: similarities and differences in depression and schizophrenia. Curr Top Behav Neurosci 2015 [Epub ahead of print].
14. Bardgett ME, Depenbrock M, Downs N, Points M, Green L. Dopamine modulates effort-based decision-making in rats. Behav Neurosci 2009; 123: 242-51.
15. Baum WM, Rachlin HC. Choice as time allocation. J Exp Anal Behav 1969; 12: 861-74.
16. Beeler JA, Frazier CR, Zhuang X. Putting desire on a budget: dopamine and energy expenditure, reconciling reward and resources. Front Integr Neurosci 2012; 6: 49.
17. Beeler JA, Faust RP, Turkson S, Ye H, Zhuang X. Low dopamine D2 receptor increases vulnerability to obesity via reduced physical activity not increased appetitive motivation. Biol Psychiatry 2015 [Epub ahead of print].
18. Beierholm U, Guitart-Masip M, Economides M, Chowdhury R, Duzel E, Dolan R, et al. Dopamine modulates reward-related vigor. Neuropsychopharmacology 2013; 38: 1495-503.
19. Belin D, Jonkman S, Dickinson A, Robbins TW, Everitt BJ. Parallel and interactive learning processes within the basal ganglia: relevance for the understanding of addiction. Behav Brain Res 2009; 199: 89-102.
20. Bell DS, Shipman WM, Cleves MA, Siegelman J. Which drug for which patient Is there a fluoxetine responding versus a bupropion responding personality profile Clin Pract Epidemiol Ment Health 2013; 9: 142-7.
21. Bentzley BS, Fender KM, Aston-Jones G. The behavioral economics of drug self-administration: a review and new analytical approach for within-session procedures. Psychopharmacology 2013; 226: 113-25.
22. Bentzley BS, Jhou TC, Aston-Jones G. Economic demand predicts addiction-like behavior and therapeutic efficacy of oxytocin in the rat. Proc Natl Acad Sci USA 2014; 111: 11822-7.
23. Bentzley BS, Aston-Jones G. Orexin-1 receptor signaling increases motivation for cocaine-associated cues. Eur J Neurosci 2015; 41: 1149-56.
24. Berlin I, Givry-Steiner L, Lecrubier Y, Puech AJ. Measures of anhedonia and hedonic responses to sucrose in depressive and schizophrenic patients in comparison with healthy subjects. Eur Psychiatry 1998; 13: 303-9.
25. Berridge KC. The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology (Berl) 2007; 191: 391-431.
26. Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience Brain Res Brain Res Rev 1998; 28: 309-69.
27. Berridge KC, Robinson TE. Parsing reward. Trends Neurosci 2003; 26: 507-13.
28. Review. Erratum in: Trends Neurosci. 2003; 26: 581.
29. Berridge KC, Kringelbach ML. Pleasure systems in the brain. [Review]. Neuron 2015; 86: 646-64.
30. Bickel WK, Green L, Vuchinich RE. Behavioral economics. J Exp Anal Behav 1995; 64: 257-62.
31. Brody AL, Barsom MW, Bota RG, Saxena S. Prefrontal-subcortical and limbic circuit mediation of major depressive disorder. Semin Clin Neuropsychiatry 2001; 6: 102-12.
32. Brown AS, Gershon S. Dopamine and depression. J Neural Transm Gen Sect 1993; 91: 75-109.
33. Botvinick MM, Huffstetler S, McGuire JT. Effort discounting in human nucleus accumbens. Cogn Affect Behav Neurosci 2009; 9: 16-27.
34. Cagniard B, Balsam PD, Brunner D, Zhuang X. Mice with chronically elevated dopamine exhibit enhanced motivation, but not learning, for a food reward. Neuropsychopharmacology 2006; 31: 1362-70.
35. Caligiuri MP, Ellwanger J. Motor and cognitive aspects of motor retardation in depression. J Affect Disord 2000; 57: 83-93.
36. Capuron L, Pagnoni G, Demetrashvili M, Woolwine BJ, Nemeroff CB, Berns GS, et al. Anterior cingulate activation and error processing during interferon-alpha treatment. Biol Psychiatry 2005; 58: 190-6.
37. Capuron L, Pagnoni G, Demetrashvili MF, Lawson DH, Fornwalt FB, Woolwine B, et al. Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacology 2007; 32: 2384-92.
38. Capuron L, Fornwalt FB, Knight BT, Harvey PD, Ninan PT, Miller AH. Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals J Affect Disord 2009; 119: 181-5.
39. Carlson NR. Physiology of behavior. Harlow, Essex, UK: Pearson Education Ltd.; 2014. p. 401-42.
40. Cattaneo A, Gennarelli M, Uher R, Breen G, Farmer A, Aitchison KJ, et al. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'. Neuropsychopharmacology 2013; 38: 377-85.
41. Caul WF, Brindle NA. Schedule-dependent effects of haloperidol and amphetamine: multiple-schedule task shows within-subject effects. Pharmacol Biochem Behav 2001; 68: 53-63.
42. Chen JJ, Ondo WG, Dashtipour K, Swope DM. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. [Review]. Clin Ther 2012; 34: 1487-504.
43. Chong TT, Bonnelle V, Manohar S, Veromann KR, Muhammed K, Tofaris GK, et al. Dopamine enhances willingness to exert effort for reward in Parkinson's disease. Cortex 2015; 69: 40-6.
44. Clarke DE, Ko JY, Kuhl EA, van Reekum R, Salvador R, Marin RS. Are the available apathy measures reliable and valid A review of the psychometric evidence. J Psychosom Res 2011; 70: 73-97.
45. Clepce M, Gossler A, Reich K, Kornhuber J, Thuerauf N. The relation between depression, anhedonia and olfactory hedonic estimates-a pilot study in major depression. Neurosci Lett 2010; 471: 139-43.
46. Cley-Melin ML, Schmidt L, Lafargue G, Baup N, Fossati P, Pessiglione M. Why don't you try harder An investigation of effort production in major depression. PLoS One 2011; 6: e23178.
47. Cofer CN, Appley MH. Motivation: theory and research. New York: John Wiley and Sons; 1964.
48. Collins AG, Frank MJ. Opponent actor learning (OpAL): modeling interactive effects of striatal dopamine on reinforcement learning and choice incentive. Psychol Rev 2014; 121: 337-66.
49. Corbit LH, Balleine BW. The general and outcome-specific forms of Pavlovian-instrumental transfer are differentially mediated by the nucleus accumbens core and shell. J Neurosci 2011; 31: 11786-94.
50. Corbit LH, Janak PH. Posterior dorsomedial striatum is critical for both selective instrumental and Pavlovian reward learning. Eur J Neurosci 2010; 31: 1312-21.
51. Corbit LH, Muir JL, Balleine BW. The role of the nucleus accumbens in instrumental conditioning: evidence of a functional dissociation between accumbens core and shell. J Neurosci 2001; 21: 3251-60.
52. Correa M, Carlson BB, Wisniecki A, Salamone JD. Nucleus accumbens dopamine and work requirements on interval schedules. Behav Brain Res 2002; 137: 179-87.
53. Cooper JA, Tucker VL, Papakostas GI. Resolution of sleepiness and fatigue: a comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union. J Psychopharmacol 2014; 28: 118-24.
54. Cousins MS, Sokolowski JD, Salamone JD. Different effects of nucleus accumbens and ventrolateral striatal (DA) depletions on instrumental response selection in the rat. Pharmacol Biochem Behav 1993; 46: 943-51.
55. Cousins MS, Atherton A, Turner L, Salamone JD. Nucleus accumbens (DA) depletions alter relative response allocation in a T-maze cost/benefit task. Behav Brain Res 1996; 74: 189-97.
56. Croxson PL, Walton ME, O'Reilly JX, Behrens TE, Rushworth MF. Effort-based cost-benefit valuation and the human brain. J Neurosci 2009; 29: 4531-41.
57. Cuthbert BN, Insel TR. Toward the future of psychiatric diagnosis: the seven pillars of RDoC. BMC Med 2013; 11: 126.
58. Dalley JW, Laane K, Theobald DE, Armstrong HC, Corlett PR, Chudasama Y, et al. Time-limited modulation of appetitive Pavlovian memory by D1 and NMDA receptors in the nucleus accumbens. Proc Natl Acad Sci USA 2005; 102: 6189-94.
59. Damiano CR, Aloi J, Treadway M, Bodfish JW, Dichter GS. Adults with autism spectrum disorders exhibit decreased sensitivity to reward parameters when making effort-based decisions. J Neurodev Disord 2012; 4: 13.
60. Dantzer R. Cytokine, sickness behavior, and depression. Immunol Allergy Clin North Am 2009; 29: 247-64.
61. Dantzer R, Capuron L, Irwin MR, Miller AH, Ollat H, Perry VH, et al. Identification and treatment of symptoms associated with inflammation in medically ill patients. Psychoneuroendocrinology 2008; 33: 18-29.
62. Dantzer R, Meagher MW, Cleeland CS. Translational approaches to treatment-induced symptoms in cancer patients. [Review]. Nat Rev Clin Oncol 2012; 9: 414-26.
63. Davis MC, Horan WP, Marder SR. Psychopharmacology of the negative symptoms: current status and prospects for progress. Eur Neuropsychopharmacol 2014; 24: 788-99.
64. de Jong JW, Roelofs TJ, Mol FM, Hillen AE, Meijboom KE, Luijendijk MC, et al. Reducing ventral tegmental dopamine D2 receptor expression selectively boosts incentive motivation. Neuropsychopharmacology 2015; 40: 2085-95.
65. Delfs JM, Schreiber L, Kelley AE. Microinjection of cocaine into the nucleus accumbens elicits locomotor activation in the rat. J Neurosci 1990; 10: 303-10.
66. Demyttenaere K, De Fruyt J, Stahl SM. The many faces of fatigue in major depressive disorder. Int J Neuropsychopharmacol 2005; 8: 93-105.
67. Denk F, Walton ME, Jennings KA, Sharp T, Rushworth MF, Bannerman DM. Differential involvement of serotonin and dopamine systems in cost-benefit decisions about delay or effort. Psychopharmacology (Berl) 2005; 179: 587-96.
68. Devos D, Moreau C, Delval A, Dujardin K, Defebvre L, Bordet R. Methylphenidate: a treatment for Parkinson's disease CNS Drugs 2013; 27: 1-14.
69. Dichter GS. Anhedonia in unipolar major depressive disorder: a review. Open Psychiatry J 2010; 4: 1-9.
70. Dichter GS, Smoski MJ, Kampov-Polevoy AB, Gallop R, Garbutt JC. Unipolar depression does not moderate responses to the Sweet Taste Test. Depress Anxiety 2010; 27: 859-63.
71. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67: 446-57.
72. Drew MR, Simpson EH, Kellendonk C, Herzberg WG, Lipatova O, Fairhurst S, et al. Transient overexpression of striatal D2 receptors impairs operant motivation and interval timing. J Neurosci 2007; 27: 7731-9.
73. Duffy E. Activation and behavior. New York: John Wiley and Sons; 1963.
74. Elbers R, van Wegen EE, Rochester L, Hetherington V, Nieuwboer A, Willems AM, et al. Is impact of fatigue an independent factor associated with physical activity in patients with idiopathic Parkinson's disease Mov Disord 2009; 24: 1512-8.
75. Fabre LF, Brodie HK, Garver D, Zung WW. A multicenter evaluation of bupropion versus placebo in hospitalized depressed patients. J Clin Psychiatry 1983; 44: 88-94.
76. Farrar AM, Pereira M, Velasco F, Hockemeyer J, Muller CE, Salamone JD. Adenosine A(2A) receptor antagonism reverses the effects of (DA) receptor antagonism on instrumental output and effort-related choice in the rat: implications for studies of psychomotor slowing. Psychopharmacology 2007; 191: 579-86.
77. Farrar AM, Font L, Pereira M, Mingote SM, Bunce JG, Chrobak JJ, et al. Forebrain circuitry involved in effort-related choice: injections of the GABAA agonist muscimol into ventral pallidum alters response allocation in food-seeking behavior. Neuroscience 2008; 152: 321-30.
78. Farrar AM, Segovia KN, Randall PA, Nunes EJ, Collins LE, Stopper CM, et al. Nucleus accumbens and effort-related functions: behavioral and neural markers of the interactions between adenosine A2A and (DA) D2 receptors. Neuroscience 2010; 166: 1056-67.
79. Faustman WO, Fowler SC. Use of operant response duration to distinguish the effects of haloperidol from nonreward. Pharmacol Biochem Behav 1981; 15: 327-9.
80. Fava M, Ball S, Nelson JC, Sparks J, Konechnik T, Classi P, et al. Clinical relevance of fatigue as a residual symptom in major depressive disorder. [Review] Depress Anxiety 2014; 31: 250-7.
81. Felger JC, Li L, Marvar PJ, Woolwine BJ, Harrison DG, Raison CL, et al. Tyrosine metabolism during interferon-alpha administration: association with fatigue and CSF dopamine concentrations. Brain Behav Immun 2013; 153-60.
82. Ferre S, Quiroz C, Woods AS, Cunha R, Popoli P, Ciruela F, et al. An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors [Review]. Curr Pharm Des 2008; 14: 1468-74.
83. Fervaha G, Foussias G, Agid O, Remington G. Neural substrates underlying effort computation in schizophrenia. Neurosci Biobehav Rev 2013; 37: 2649-65.
84. Fernando AB, Urcelay GP, Mar AC, Dickinson TA, Robbins TW. The role of the nucleus accumbens shell in the mediation of the reinforcing properties of a safety signal in free-operant avoidance: dopamine-dependent inhibitory effects of d-amphetamine. Neuropsychopharmacology 2014; 39: 1420-30.
85. Fervaha G, Duncan M, Foussias G, Agid O, Faulkner GE, Remington G. Effort-based decision-making as an objective paradigm for the assessment of motivational deficits in schizophrenia. Schizophr Res 2015; 168: 483-90. pii: S0920-9964(15)00388-6.
86. Floresco SB. The nucleus accumbens: an interface between cognition, emotion, and action. Annu Rev Psychol 2015; 66: 25-52.
87. Floresco SB, Ghods-Sharifi S. Amygdala-prefrontal cortical circuitry regulates effort-based decision making. Cereb Cortex 2007; 17: 251-60.
88. Floresco SB, Tse MT, Ghods-Sharifi S. Dopaminergic and glutamatergic regulation of effort-and delay-based decision-making. Neuropsychopharmacology 2008; 33: 1966-79.
89. Font L, Mingote S, Farrar AM, Pereira M, Worden L, Stopper C, et al. Intra-accumbens injections of the adenosine A2A agonist CGS 21680 affect effort-related choice behavior in rats. Psychopharmacology 2008; 199: 515-26.
90. Foussias G, Siddiqui I, Fervaha G, Mann S, McDonald K, Agid O, et al. Motivated to do well: an examination of the relationships between motivation, effort, and cognitive performance in schizophrenia. Schizophr Res 2015; 166: 276-82.
91. Fowler SC, LaCerra MM, Ettenberg A. Effects of haloperidol on the biophysical characteristics of operant responding: implications for motor and reinforcement processes. Pharmacol Biochem Behav 1986; 25: 791-6.
92. Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRAHD Investigators. BMC Neurol 2009; 9: 62.
93. Frank S. Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease. Neuropsychiatr Dis Treat 2010; 6: 657-65.
94. Friedman JH, Brown RG, Comella C, Garber CE, Krupp LB, Lou JS, et al. Fatigue in Parkinson's disease: a review. [Review]. Mov Disord 2007; 22: 297-308.
95. Gard DE, Kring AM, Gard MG, Horan WP, Green MF. Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure. Schizophr Res 2007; 93: 253-60.
96. Gard DE, Fisher M, Garrett C, Genevsky A, Vinogradov S. Motivation and its relationship to neurocognition, social cognition, and functional outcome in schizophrenia. Schizophr Res 2009; 115: 74-81.
97. Gard DE, Sanchez AH, Cooper K, Fisher M, Garrett C, Vinogradov S. Do people with schizophrenia have difficulty anticipating pleasure, engaging in effortful behavior, or both J Abnorm Psychol 2014; 123: 771-82.
98. Gerber AJ, Posner J, Gorman D, Colibazzi T, Yu S, Wang Z, et al. An affective circumplex model of neural systems subserving valence, arousal, and cognitive overlay during the appraisal of emotional faces. Neuropsychologia 2008; 46: 2129-39.
99. Ghods-Sharifi S, Floresco SB. Differential effects on effort discounting induced by inactivations of the nucleus accumbens core or shell. Behav Neurosci 2010; 124: 179-91.
100. dopamine transporter as measured by positron emission tomography. Biol Psychiat 2003; 54: 800-5.
101. Lex A, Hauber W. Dopamine D1 and D2 receptors in the nucleus accumbens core and shell mediate Pavlovian-instrumental transfer. Learn Mem 2008; 15: 483-91.
102. Lex B, Hauber W. The role of nucleus accumbens dopamine in outcome encoding in instrumental and Pavlovian conditioning. Neurobiol Learn Mem 2010; 93: 283-90.
103. Lopez-Crespo G, Rodriguez M, Pellon R, Flores P. Acquisition of schedule-induced polydipsia by rats in proximity to upcoming food delivery. Learn Behav 2004; 32: 491-9.
104. Lotrich FE. Major depression during interferon-alpha treatment: vulnerability and prevention. Dialogues Clin Neurosci 2009; 11: 417-25.
105. Madden GJ, Kalman D. Effects of bupropion on simulated demand for cigarettes and the subjective effects of smoking. Nicotine Tobacco Res 2010; 12: 416-22.
106. Madden GJ, Bickel WK, Jacobs EA. Three predictions of the economic concept of unit price in a choice context. J Exp Anal Behav 2000; 73: 45-64.
107. Madden GJ, Smethells JR, Ewan EE, Hursh SR. Tests of behavioraleconomic assessments of relative reinforcer efficacy II: economic complements. J Exp Anal Behav 2007; 88: 355-67.
108. Mai B, Sommer S, Hauber W. Motivational states influence effortbased decision-making in rats: the role of dopamine in the nucleus accumbens. Cogn Affect Behav Neurosci 2012; 12: 74-84.
109. Majer M, Welberg LA, Capuron L, Pagnoni G, Raison CL, Miller AH. IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C. Brain Behav Immun 2008; 22: 870-80.
110. Marinelli M, McCutcheon JE. Heterogeneity of dopamine neuron activity across traits and states. Neuroscience 2014; 282C: 176-97.
111. Markou A, Salamone JD, Bussey TJ, Mar AC, Brunner D, Gilmour G, et al. Measuring reinforcement learning and motivation constructs in experimental animals: relevance to the negative symptoms of schizophrenia. [Review]. Neurosci Biobehav Rev 2013; 37: 2149-65.
112. McGinty VB, Lardeux S, Taha SA, Kim JJ, Nicola SM. Invigoration of reward seeking by cue and proximity encoding in the nucleus accumbens. Neuron 2013; 78: 910-22.
113. McCullough LD, Salamone JD. Involvement of nucleus accumbens dopamine in the motor activity induced by periodic food presentation: a microdialysis and behavioral study. Brain Res 1992; 592: 29-36.
114. McCullough LD, Cousins MS, Salamone JD. The role of nucleus accumbens dopamine in responding on a continuous reinforcement operant schedule: a neurochemical and Behavioral study. Pharmacol Biochem Behav 1993a; 46: 581-6.
115. McCullough LD, Sokolowsi JD, Salamone JD. A neurochemical and behavioral investigation of the involvement of nucleus accumbens dopamine in instrumental avoidance. Neuroscience 1993b; 52: 919-25.
116. Miller AH, Norman Cousins Lecture. Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface. Brain Behav Immun 2009; 23: 149-58.
117. Mingote S, Weber SM, Ishiwari K, Correa M, Salamone JD. Ratio and time requirements on operant schedules: effort-related effects of nucleus accumbens dopamine depletions. Europ J Neurosci 2005; 21: 1749-57.
118. Mingote S, Font L, Farrar AM, Vontell R, Worden LT, Stopper CM, et al. Nucleus accumbens adenosine A2A receptors regulate exertion of effort by acting on the ventral striatopallidal pathway. J Neurosci 2008; 28: 9037-46.
119. Moschak TM, Mitchell SH. Partial inactivation of nucleus accumbens core decreases delay discounting in rats without affecting sensitivity to delay or magnitude. Behav Brain Res 2014; 268: 159-68.
120. Mott AM, Nunes EJ, Collins LE, Port RG, Sink KS, Hockemeyer J, et al. The adenosine A2A antagonist MSX-3 reverses the effects of the (DA) antagonist haloperidol on effort-related decision-making in a T-maze cost/benefit procedure. Psychopharmacology 2009; 204: 103-12.
121. Nicola SM. The flexible approach hypothesis: unification of effort and cue-responding hypotheses for the role of nucleus accumbens dopamine in the activation of reward-seeking behavior. J Neurosci 2010; 30: 16585-600.
122. Niv Y, Daw ND, Joel D, Dayan P. Tonic dopamine: opportunity costs and the control of response vigor. Psychopharmacology 2007; 191: 507-20.
123. Nomoto M, Nagai M, Nishikawa N. Clinical nonmotor aspect of A2A antagonist in PD treatment. Int Rev Neurobiol 2014; 119: 191-4.
124. Nowend KL, Arizzi M, Carlson BB, Salamone JD. D1 or D2 antagonism in nucleus accumbens core or dorsomedial shell suppresses lever pressing for food but leads to compensatory increases in chow consumption. Pharmacol Biochem Behav 2001; 69: 373-82.
125. Nunes EJ, Randall PA, Estrada A, Epling B, Hart EE, Lee CA, et al. Effort-related motivational effects of the pro-inflammatory cytokine interleukin 1-beta: studies with the concurrent fixed ratio 5/chow feeding choice task. Psychopharmacology (Berl) 2014; 23: 727-36.
126. Nunes EJ, Randall PA, Santerre JL, Given AB, Sager TN, Correa M, et al. Differential effects of selective adenosine antagonists on the effort-related impairments induced by (DA) D1 and D2 antagonism. Neuroscience 2010; 170: 268-80.
127. Nunes EJ, Randall PA, Podurgiel S, Correa M, Salamone JD. Nucleus accumbens neurotransmission and effort-related choice behavior in food motivation: effects of drugs acting on dopamine, adenosine, and muscarinic acetylcholine receptors. Neurosci Biobehav Rev 2013a; 37: 2015-25.
128. Nunes EJ, Randall PA, Hart EE, Freeland C, Yohn SE, Baqi Y, et al. Effort-related motivational effects of the VMAT-2 inhibitor tetrabenazine: implications for animal models of the motivational symptoms of depression. J Neurosci 2013b; 33: 19120-30.
129. Nutt D, Demyttenaere K, Janka Z, Aarre T, Bourin M, Canonico PL, et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. [Review]. J Psychopharmacol 2007; 21: 461-71.
130. Pae CU, Lim HK, Han C, Patkar AA, Steffens DC, Masand PS, et al. Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion. [Review]. Expert Rev Neurother 2007; 7: 1251-63.
131. Padala PR, Padala KP, Monga V, Ramirez DA, Sullivan DH. Reversal of SSRI associated apathy syndrome by discontinuation of therapy. Ann Pharmacother 2012; 46: e8.
132. Papakostas GI, Nutt DJ, Hallett LA, Tucker VL, Krishen A, Fava M. Resolution of sleepiness and fatigue in major depressive disorder: a comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry 2006; 60: 1350-5.
133. Papakostas GI, Stahl SM, Krishen A, Seifert CA, Tucker VL, Goodale EP, et al. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. J Clin Psychiatry 2008; 69: 1287-92.
134. Pardo M, Lopez-Cruz L, Valverde O, Ledent C, Baqi Y, Muller CE, et al. Adenosine A2A receptor antagonism and genetic deletion attenuate the effects of dopamine D2 antagonism on effort-related decision-making in mice. Neuropharmacology 2012; 62: 2068-77.
135. Pardo M, Lopez-Cruz L, Miguel NS, Salamone JD, Correa M. Selection of sucrose concentration depends on the effort required to obtain it: studies using tetrabenazine, D1, D2, and D3 receptor antagonists. Psychopharmacology 2015; 232: 2377-91.
136. Parkinson JA, Dalley JW, Cardinal RN, Bamford A, Fehnert B, Lachenal G, et al. Nucleus accumbens dopamine depletion impairs both acquisition and performance of appetitive Pavlovian approach behaviour: implications for mesoaccumbens dopamine function. Behav Brain Res 2002; 137: 149-63.
137. Peciñ a S, Cagniard B, Berridge KC, Aldridge JW, Zhuang X. Hyperdopaminergic mutant mice have higher "wanting" but not "liking" for sweet rewards. J Neurosci 2003; 23: 9395-402.
138. Pereira M, Ferreira A. Demanding pups improve maternal behavioral impairments in sensitized and haloperidol-treated lactating female rats. Behav Brain Res 2006; 175: 139-48.
139. Pereira M, Ferreira A. Neuroanatomical and neurochemical basis of parenting: dynamic coordination of motivational, affective and cognitive processes. Horm Behav 2015; 77: 72-85.
140. Pettibone DJ, Totaro JA, Pflueger AB. Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants. Eur J Pharmacol 1984; 102: 425-30.
141. Phillips PE, Walton ME, Jhou TC. Calculating utility: preclinical evidence for cost-benefit analysis by mesolimbic dopamine. Psychopharmacology 2007; 191: 483-95.
142. Piser TM. Linking the cytokine and neurocircuitry hypotheses of depression: a translational framework for discovery and development of novel anti-depressants. Brain Behav Immun 2010; 24: 515-24.
143. Pizzagalli DA. Depression, stress, and anhedonia: toward a synthesis and integrated model. Annu Rev Clin Psychol 2014; 10: 393-423.
144. Preskorn SH, Kent TA, Glotzbach RK, Irwin GH, Solnick JV. Cerebromicrocirculatory defects in animal model of depression. Psychopharmacology (Berl) 1984; 84: 196-9.
145. Porat O, Hassin-Baer S, Cohen OS, Markus A, Tomer R. Asymmetric dopamine loss differentially affects effort to maximize gain or minimize loss. Cortex 2014; 51: 82-91.
146. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. [Review]. Trends Immunol 2006; 27: 24-31.
147. Rampello L, Nicoletti G, Raffaele R. Dopaminergic hypothesis for retarded depression: a symptom profile for predicting therapeutical responses. Acta Psychiatr Scand 1991; 84: 552-4.
148. Randall PA, Pardo M, Nunes EJ, Lopez Cruz L, Vemuri VK, Makriyannis A, et al. Dopaminergic modulation of effort-related choice behavior as assessed by a progressive ratio chow task: pharmacological studies and role of individual differences. PLoS One 2012; 7: e47934.
149. Randall PA, Lee CA, Nunes EJ, Yohn SE, Nowak V, Khan B, et al. The VMAT-2 inhibitor tetrabenazine affects effort-related decision making in a progressive ratio/chow feeding choice task: reversal with antidepressant drugs. PLoS One 2014; 9: e99320.
150. Randall PA, Lee CA, Podurgiel SJ, Hart E, Yohn SE, Jones M, et al. Bupropion increases selection of high effort activity in rats tested on progressive ratio/chow feeding choice procedure: implications for treatment of effort-related motivational symptoms. Int J Neuropsychopharmacol 2015; 18.
151. Reddy LF, Horan WP, Barch DM, Buchanan RW, Dunayevich E, Gold JM, et al. Effort-based decision-making paradigms for clinical trials in schizophrenia: part 1-psychometric characteristics of 5 paradigms. Schizophr Bull 2015a; 41: 1045-54.
152. Reddy LF, Horan WP, Green MF. Motivational deficits and negative symptoms in schizophrenia: concepts and assessments. Curr Top Behav Neurosci 2015b [Epub ahead of print].
153. Ribot, T., 1896. La psychologie des sentiment (The Psychology of Feelings). Felix Alcan, Paris.
154. Rick JH, Horvitz JC, Balsam PD. Dopamine receptor blockade and extinction differentially affect behavioral variability. Behav Neurosci 2006; 120: 488-92.
155. Rizvi SJ, Geraci J, Ravindran A, Kennedy SH. Predictors of response to adjunctive osmotic-release methylphenidate or placebo in patients with major depressive disorder: effects of apathy/anhedonia and fatigue. J Clin Psychopharmacol 2014; 34: 755-9.
156. Robbins TW, Everitt BJ. A role for mesencephalic dopamine in activation: commentary on Berridge (2006). [Review]. Psychopharmacology 2007; 191: 433-7.
157. Robbins TW, Koob GF. Selective disruption of displacement behaviour by lesions of the mesolimbic dopamine system. Nature 1980; 285: 409-12.
158. Robbins TW, Roberts DC, Koob GF. Effects of d-amphetamine and apomorphine upon operant behavior and schedule-induced licking in rats with 6-hydroxydopamine-induced lesions of the nucleus accumbens. J Pharmacol Exp Ther 1983; 224: 662-73.
159. Rogers D, Lees AJ, Smith E, Trimble M, Stern GM. Bradyphrenia in Parkinson's disease and psychomotor retardation in depressive illness. An experimental study. Brain 1987; 110: 761-76.
160. Rogers DC, Costall B, Domeney AM, Gerrard PA, Greener M, Kelly ME, et al. Anxiolytic profile of ropinirole in the rat, mouse and common marmoset. Psychopharmacology (Berl) 2000; 151: 91-7.
161. Rosin DL, Robeva A, Woodard RL, Guyenet PG, Linden J. Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system. J Comp Neurol 1998; 401: 163-86.
162. Rothschild AJ, Raskin J, Wang CN, Marangell LB, Fava M. The relationship between change in apathy and changes in cognition and functional outcomes in currently non-depressed SSRI-treated patients with major depressive disorder. Compr Psychiatry 2014; 55: 1-10.
163. Salamone JD. Different effects of haloperidol and extinction on instrumental behaviours. Psychopharmacology (Berl) 1986; 88: 18-23.
164. Salamone JD. The actions of neuroleptic drugs on appetitive instrumental behaviors. In: Iversen LL, Iversen SD, Snyder SH, editors. Handbook of psychopharmacology. New York: Plenum Press; 1987., p. 575-608.
165. Salamone JD. Dopaminergic involvement in activational aspects of motivation: effects of haloperidol on schedule induced activity, feeding and foraging in rats. Psychobiology 1988; 16: 196-206.
166. Salamone JD. Behavioral pharmacology of dopamine systems: a new synthesis. In: Willner P, Scheel-Kruger J, editors. The mesolimbic dopamine system: from motivation to action. Cambridge, England: Cambridge University Press; 1991. p. 599-613.
167. Salamone JD. Complex motor and sensorimotor functions of striatal and accumbens dopamine: involvement in instrumental behavior processes. Psychopharmacology (Berl) 1992; 107: 160-74.
168. Salamone JD. Involvement of nucleus accumbens dopamine in appetitive and aversive motivation. Behav Brain Res 1994; 61: 117-33.
169. Salamone JD. Preladenant, a novel adenosine A(2A) receptor antagonist for the potential treatment of parkinsonism and other disorders. IDrugs 2010; 13: 723-31.
170. Salamone JD, Correa M. Motivational views of reinforcement: implications for understanding the behavioral functions of nucleus accumbens dopamine. [Review]. Behav Brain Res 2002; 137: 3-25.
171. Salamone JD, Correa M. Dopamine/adenosine interactions involved in effort-related aspects of food motivation. [Review]. Appetite 2009; 53: 422-5.
172. Salamone JD, Correa M. The mysterious motivational functions of mesolimbic dopamine. Neuron 2012; 76: 470-85.
173. Salamone JD, Steinpreis RE, McCullough LD, Smith P, Grebel D, Mahan K. Haloperidol and nucleus accumbens dopamine depletion suppress lever pressing for food but increase free food consumption in a novel food-choice procedure. Psychopharmacology 1991; 104: 515-21.
174. Salamone JD, Cousins MS, Bucher S. Anhedonia or anergia Effects of haloperidol and nucleus accumbens (DA) depletion on instrumental response selection in a T-maze cost/benefit procedure. Behav Brain Res 1994a; 65: 221-9.
175. Salamone JD, Cousins MS, McCullough LD, Carriero DL, Berkowitz RJ. Nucleus accumbens dopamine release increases during instrumental lever pressing for food but not free food consumption. Pharmacol Biochem Behav 1994b; 49: 25-31.
176. Salamone JD, Kurth P, McCullough LD, Sokolowski JD. The effects of nucleus accumbens dopamine depletions on continuously reinforced operant responding: contrasts with the effects of extinction. Pharmacol Biochem Behav 1995; 50: 437-43.
177. Salamone JD, Cousins MS, Snyder BJ. Behavioral functions of nucleus accumbens DA: empirical and conceptual problems with the anhedonia hypothesis. Neurosci Biobehav Rev 1997; 21: 341-59.
178. Salamone JD, Arizzi MN, Sandoval MD, Cervone KM, Aberman JE. Dopamine antagonists alter response allocation but do not suppress appetite for food: contrasts between the effects of SKF 83566, raclopride and fenfluramine on a concurrent lever pressing/chow consumption task. Psychopharmacology 2002; 160: 371-80.
179. Salamone JD, Correa M, Mingote S, Weber SM. Nucleus accumbens dopamine and the regulation of effort in food-seeking behavior: implications for studies of natural motivation, psychiatry, and drug abuse. [Review]. J Pharmacol Exp Ther 2003; 305: 1-8.
180. Salamone JD, Correa M. Insulin and ventral tegmental dopamine: what's impaired and what's intact. Cell Metab 2013; 17: 469-70.
181. Salamone JD, Correa M, Mingote SM, Weber SM. Beyond the reward hypothesis: alternative functions of nucleus accumbens dopamine. Curr Opin Pharmacol 2005; 5: 34-41.
182. Salamone JD, Correa M, Mingote SM, Weber SM, Farrar AM. Nucleus Accumbens (DA) and the forebrain circuitry involved in behavioral activation and effort-related decision-making: implications for understanding anergia and psychomotor slowing in depression. Curr Psychiatry Rev 2006; 178: 267-80.
183. Salamone JD, Correa M, Farrar A, Mingote SM. Effort-related functions of nucleus accumbens (DA) and associated forebrain circuits. Psychopharmacology 2007; 191: 461-82.
184. Salamone JD, Correa M, Yohn S, Lopez Cruz L., San Miguel N, Alatorre L. The pharmacology of effort-related choice behavior: Dopamine, depression, and individual differences. Behav Processes 2016; [Epub ahead of print].
185. Salamone JD, Farrar AM, Font L, Patel V, Schlar DE, Nunes EJ, et al. Differential actions of adenosine A1 and A2A antagonists on the effort-related effects of (DA) D2 antagonism. Behav Brain Res 2009; 201: 216-22.
186. Salamone JD, Correa M, Farrar AM, Nunes EJ, Collins LE. The role of (DA)/adenosine interactions in the brain circuitry regulating effort-related decision-making: insights into pathological aspects of motivation. Future Neurology 2010; 5: 377-92.
187. Salamone JD, Correa M, Nunes EJ, Randall PA, Pardo M. The behavioral pharmacology of effort-related choice behavior: dopamine, adenosine and beyond. J Exp Anal Behav 2012; 97: 125-46.
188. Salamone JD, Koychev I, Correa M, McGuire P. Neurobiological basis of motivational deficits in psychopathology. Eur Neuropsychopharmacol 2015a; 25: 1225-38.
189. Salamone JD, Pardo M, Yohn SE, Lopez-Cruz L, San Miguel N, Correa M. Mesolimbic Dopamine and the Regulation of Motivated Behavior. In: Current Topics in Behavioral Neurosciences. Springer: Heidelberg; 1987. p. 1-27.
190. Salamone JD, Wisniecki A, Carlson BB, Correa M. Nucleus accumbens dopamine depletions make animals highly sensitive to high fixed ratio requirements but do not impair primary food reinforcement. Neuroscience 2001; 105: 863-70.
191. Santerre JL, Nunes EJ, Kovner R, Leser CE, Randall PA, Collins-Praino LE, et al. The novel adenosine A(2A) antagonist prodrug MSX-4 is effective in animal models related to motivational and motor functions. Pharmacol Biochem Behav 2012; 102: 477-87.
192. Schmidt K, Nolte-Zenker B, Patzer J, Bauer M, Schmidt LG, Heinz A. Psychopathological correlates of reduced dopamine receptor sensitivity in depression, schizophrenia, and opiate and alcohol dependence. Pharmacopsychiatry 2001; 34: 66-72.
193. Schmidt L, Lebreton M, Cley-Melin ML, Daunizeau J, Pessiglione M. Neural mechanisms underlying motivation of mental versus physical effort. PLoS Biol 2012; 10: e1001266.
194. Scinska A, Sienkiewicz-Jarosz H, Kuran W, Ryglewicz D, Rogowski A, Wrobel E, et al. Depressive symptoms and taste reactivity in humans. Physiol Behav 2004; 82: 899-904.
195. Sederholm F, Johnson AE, Brodin U, Sodersten P. Dopamine D(2) receptors and ingestive behavior: brainstem mediates inhibition of intraoral intake and accumbens mediates aversive taste behavior in male rats. Psychopharmacology 2002; 160: 161-9.
196. Shafiei N, Gray M, Viau V, Floresco SB. Acute stress induces selective alterations in cost/benefit decision-making. Neuropsychopharmacology 2012; 37: 2194-209.
197. Shenhav A, Botvinick MM, Cohen JD. The expected value of control: an integrative theory of anterior cingulate cortex function. Neuron 2013; 79: 217-40.
198. Shore DM, Rafal R, Parkinson JA. Appetitive motivational deficits in individuals with Parkinson's disease. Mov Disord 2011; 26: 1887-92.
199. Sienkiewicz-Jarosz H, Scinska A, Swiecicki L, Lipczynska-Lojkowska W, Kuran W, Ryglewicz D, et al. Sweet liking in patients with Parkinson's disease. J Neurol Sci 2013; 329: 17-22.
200. Simpson EH, Kellendonk C, Ward RD, Richards V, Lipatova O, Fairhurst S, et al. Pharmacologic rescue of motivational deficit in an animal model of the negative symptoms of schizophrenia. Biol Psychiatry 2011; 69: 928-35.
201. Sink KS, Vemuri VK, Olszewska T, Makriyannis A, Salamone JD. Cannabinoid CB1 antagonists and dopamine antagonists produce different effects on a task involving response allocation and effortrelated choice in food-seeking behavior. Psychopharmacology 2008; 196: 565-74.
202. Smith RS. The macrophage theory of depression. Med Hypotheses 1991; 35: 298-306.
203. Erratum in: Med Hypotheses 1991; 36(2):178.
204. Smith KS, Berridge KC, Aldridge JW. Disentangling pleasure from incentive salience and learning signals in brain reward circuitry. Proc Natl Acad Sci USA 2011; 108: E255-64.
205. Sommer S, Danysz W, Russ H, Valastro B, Flik G, Hauber W. The dopamine reuptake inhibitor MRZ-9547 increases progressive ratio responding in rats. Int J Neuropsychopharmacol 2014; 17: 2045-56.
206. Staddon JER, Simmelhag VL. The "superstition" experiment: a reexamination of its implications for the principles of adaptive behavior. Psychol Rev 1971; 78: 3-43.
207. Stahl SM. The psychopharmacology of energy and fatigue. J Clin Psychiat 2002; 63: 7-8.
208. Stenman E, Lilja A. Increased monoaminergic neurotransmission improves compliance with physical activity recommendations in depressed patients with fatigue. Med Hypotheses 2013; 80: 47-9.
209. Stotz G, Woggon B, Angst J. Psychostimulants in the therapy of treatment-resistant depression Review of the literature and findings from a retrospective study in 65 depressed patients. Dialogues Clin Neurosci 1999; 1: 165-74.
210. Svenningsson P, Le Moine C, Fisone G, Fredholm BB. Distribution, biochemistry and function of striatal adenosine A2A receptors. [Review]. Prog Neurobiol 1999; 59: 355-96.
211. Swerdlow NR, Mansbach RS, Geyer MA, Pulvirenti L, Koob GF, Braff DL. Amphetamine disruption of prepulse inhibition of acoustic startle is reversed by depletion of mesolimbic dopamine. Psychopharmacology (Berl) 1990; 100: 413-6.
212. Tanra AJ, Kagaya A, Okamoto Y, Muraoka M, Motohashi N, Yamawaki S. TJS-010, a new prescription of oriental medicine, antagonizes tetrabenazine-induced suppression of spontaneous locomotor activity in rats. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19: 963-71.
213. Targum SD, Fava M. Fatigue as a residual symptom of depression. Innov Clin Neurosci 2011; 8: 40-3.
214. Tellez N, Alonso J, Rio M, Tintore M, Nos C, Montalban X, et al. The basal ganglia: a substrate for fatigue in multiple sclerosis. Neuroradiology 2008; 50: 17-23.
215. Tidey JW, Miczek KA. Social defeat stress selectively alters mesocorticolimbic dopamine release: an in vivo microdialysis study. Brain Res 1996; 721: 140-9.
216. Todder D, Caliskan S, Baune BT. Longitudinal changes of day-time and night-time gross motor activity in clinical responders and nonresponders of major depression. World J Biol Psychiat 2009; 10: 276-84.
217. Tombaugh TN, Anisman H, Tombaugh J. Extinction and dopamine receptor blockade after intermittent reinforcement training: failure to observe functional equivalence. Psychopharmacology 1980; 70: 19-28.
218. Treadway MT, Zald DH. Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosci Biobehav Rev 2011; 35: 537-55.
219. Treadway MT, Buckholtz JW, Schwartzman AN, Lambert WE, Zald DH. Worth the 'EEfRT' The effort expenditure for rewards task as an objective measure of motivation and anhedonia. PLoS One 2009; 4: e6598.
220. Treadway MT, Bossaller NA, Shelton RC, Zald DH. Effort-based decision-making in major depressive disorder: a translational model of motivational anhedonia. J Abnorm Psychol 2012a; 121: 553-8.
221. Treadway MT, Buckholtz JW, Cowan RL, Woodward ND, Li R, Ansari MS, et al. Dopaminergic mechanisms of individual differences in human effort-based decision-making. J Neurosci 2012b; 32: 6170-6.
222. Treadway MT, Peterman JS, Zald DH, Park S. Impaired effort allocation in patients with schizophrenia. Schizophr Res 2015; 161: 382-5.
223. Trifilieff P, Feng B, Urizar E, Winiger V, Ward RD, Taylor KM, et al. Increasing dopamine D2 receptor expression in the adult nucleus accumbens enhances motivation. Mol Psychiatry 2013; 18: 1025-33.
224. Tsapakis EM, Dimopoulou T, Tarazi FI. Clinical management of negative symptoms of schizophrenia: an update. [Review]. Pharmacol Ther 2015; 153: 135-47.
225. Tylee A, Gastpar M, Lepine JP, Mendlewicz J. DEPRES II (Depression Research in European Society II): a patient survey of the symptoms, disability and current management of depression in the community. Int Clin Psychopharmacol 1999; 14: 139-51.
226. van den Biggelaar AH, Gussekloo J, de Craen AJ, Frolich M, Stek ML, van der Mast RC, et al. Inflammation and interleukin-1 signaling network contribute to depressive symptoms but not cognitive decline in old age. Exp Gerontol 2007; 42: 693-701.
227. Varazzani C, San-Galli A, Gilardeau S, Bouret S. Noradrenaline and dopamine neurons in the reward/effort trade-off: a direct electrophysiological comparison in behaving monkeys. J Neurosci 2015; 35: 7866-77.
228. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 2001; 158: 377-82.
229. Wakabayashi KT, Fields HL, Nicola SM. Dissociation of the role of nucleus accumbens dopamine in responding to reward-predictive cues and waiting for reward. Behav Brain Res 2004; 154: 19-30.
230. Wallace M, Singer G, Finlay J, Gibson S. The effect of 6-OHDA lesions of the nucleus accumbens septum on schedule-induced drinking, wheel running and corticosterone levels in the rat. Pharmacol Biochem Behav 1983; 18: 129-36.
231. Wang H, Chen X, Li Y, Tang TS, Bezprozvanny I. Tetrabenazine is neuroprotective in Huntington's disease mice. Mol Neurodegener 2010; 5: 18.
232. Ward RD, Simpson EH, Richards VL, Deo G, Taylor K, Glendinning JI, et al. Dissociation of hedonic reaction to reward and incentive motivation in an animal model of the negative symptoms of schizophrenia. Neuropsychopharmacology 2012; 37: 1699-707.
233. Winograd-Gurvich C, Fitzgerald PB, Georgiou-Karistianis N, Bradshaw JL, White OB. Negative symptoms: a review of schizophrenia, melancholic depression and Parkinson's disease. [Review]. Brain Res Bull 2006; 70: 312-21.
234. Winstanley CA, Theobald DE, Dalley JW, Robbins TW. Interactions between serotonin and dopamine in the control of impulsive choice in rats: therapeutic implications for impulse control disorders. Neuropsychopharmacology 2005; 30: 669-82.
235. Walton ME, Bannerman DM, Alterescu K, Rushworth MFS. Functional specialization within medial frontal cortex of the anterior cingulate for evaluating effort-related decisions. J Neurosci 2003; 23: 6475-9.
236. Wardle MC, Treadway MT, Mayo LM, Zald DH, de Wit H. Amping up effort: effects of d-amphetamine on human effort-based decisionmaking. J Neurosci 2011; 31: 16597-602.
237. Westbrook A, Braver TS. Cognitive effort: a neuroeconomic approach. Cogn Affect Behav Neurosci 2015; 15: 395-415.
238. Williams BA. Reinforcement, choice, and response strength. In Atkinson RC, Herrnstein RJ, Lindsey G, Luce RD, editors. Stevens' handbook of experimental psychology, Vol. 2. New York: John Wiley and Sons; 1988; p. 167-74.
239. Whitton AE, Treadway MT, Pizzagalli DA. Reward processing dysfunction in major depression, bipolar disorder and schizophrenia. Curr Opin Psychiatry 2015; 28: 7-12.
240. Wolf DH, Satterthwaite TD, Kantrowitz JJ, Katchmar N, Vandekar L, Elliott MA, et al. Amotivation in schizophrenia: integrated assessment with behavioral, clinical, and imaging measures. Schizophr Bull 2014; 40: 1328-37.
241. Worden LT, Shahriari M, Farrar AM, Sink KS, Hockemeyer J, Muller CE, et al. The adenosine A2A antagonist MSX-3 reverses the effortrelated effects of (DA) blockade: differential interaction with D1 and D2 family antagonists. Psychopharmacology 2009; 203: 489-99.
242. Wyvell CL, Berridge KC. Intra-accumbens amphetamine increases the conditioned incentive salience of sucrose reward: enhancement of reward "wanting" without enhanced "liking" or response reinforcement. J Neurosci 2000; 20: 8122-30.
243. Yamada K, Kobayashi M, Kanda T. Involvement of adenosine A2A receptors in depression and anxiety. Int Rev Neurobiol 2014; 119: 373-93.
244. Yamada K, Kobayashi M, Mori A, Jenner P, Kanda T. Antidepressantlike activity of the adenosine A(2A) receptor antagonist, istradefylline (KW-6002), in the forced swim test and the tail suspension test in rodents. Pharmacol Biochem Behav 2013; 114-115: 23-30.
245. Yang XH, Huang J, Zhu CY, Wang YF, Cheung EF, Chan RC, et al. Motivational deficits in effort-based decision-making in individuals with subsyndromal depression, first-episode and remitted depression patients. Psychiatry Res 2014; 220: 874-82.
246. Yang XH, Huang J, Lan Y, Zhu CY, Liu XQ, Wang YF, et al. Diminished caudate and superior temporal gyrus responses to effort-based decision-making in patients with first-episode major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2015; 64: 52-9.
247. Yin HH, Ostlund SB, Balleine BW. Reward-guided learning beyond dopamine in the nucleus accumbens: the integrative functions of cortico-basal ganglia networks. Eur J Neurosci 2008; 28: 1437-48.
248. Yohn SE, Thompson C, Randall PA, Lee CA, Muller CE, Baqi Y, et al. The VMAT-2 inhibitor tetrabenazine alters effort-related decisionmaking as measured by the T-maze barrier choice task: reversal with the adenosine A2A antagonist MSX-3 and the catecholamine uptake blocker bupropion. Psychopharmacology 2015a; 232: 1313-23.
249. Yohn SE, Santerre JL, Nunes EJ, Kozak R, Podurgiel SJ, Correa M, et al. The role of dopamine D1 receptor transmission in effortrelated choice behavior: effects of D1 agonists. Pharmacol Biochem Behav 2015b; 135: 217-26.
250. Yohn SE, Lopez-Cruz L, Hutson PH, Correa M, Salamone JD. Effects of lisdexamfetamine and s-citalopram, alone and in combination, on effort-related choice behavior in the rat. Psychopharmacology 2016a; 233: 949-60.
251. Yohn SE, Collins SL, Contreras-Mora HM, Errante EL, Rowland MA, Correa M, et al. Not all antidepressants are created equal: differential effects of monoamine uptake inhibitors on effortrelated choice behavior. Neuropsychopharmacology 2016b; 41: 686-94.